Targeting JAK/STAT signaling pathway in inflammatory diseases

Current Signal Transduction Therapy

Volumn 4, Issue 3, 2009, Pages 201-221

  Malemud, Charles Jay ^a   Pearlman, Eric ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic heart failure; Cytokines; Eye diseases; Inflammation; Irritable bowel disease; Janus kinase; Rheumatoid arthritis; Signal transducers and activators of transcription; Small molecule inhibitors

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AUROTHIOMALATE; CYT 387; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN GP 130; INCB 018424; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE; JANUS KINASE 3 INHIBITOR; METHOTREXATE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PS 020613; PS 078507; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TG 101348; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WP 1066;

ALLERGIC PNEUMONITIS; ARTHRITIS; ARTICLE; CARTILAGE CELL; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; GENETIC POLYMORPHISM; GLIOMA; HEART FAILURE; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; KERATITIS; KNOCKOUT MOUSE; MYELOFIBROSIS; NEUTROPENIA; NONHUMAN; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 77149137827     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436209789057467     Document Type: Article

References (235)

1. Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. Curr Rheum Rev 2008; 4: 219-34.
2. Finckh A, Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 2008; 20: 269-75.
3. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
4. Sanchez-Muňoz, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-8.
5. Parish RC, Evans JD. Inflammation in chronic heart failure. Ann Pharmacother 2008; 42: 1002-16.
6. Vallochi AL, Commodaro AG, Schwartzman JP, Belfort R Jr, Rizzo LV. The role of cytokines in the regulation of ocular autoimmune inflammation. Cytokine Growth Factor Rev 2007; 18: 135-41.
7. Ooi KG, Galatowicz G, Calder G, Lightman SL. Cytokines and chemokines in uveitis - Is there a correlation with clinical phenotype? Clin Med Res 2006; 4: 294-309.
8. Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther 2004; 6: 159-68.
9. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007; 89: 729-34.
10. Deon D, Ahmed S, Tai K, et al. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol 2001; 167: 5395-403.
11. Murray PJ. The JAK-STAT signaling pathway: Input and output integration. J Immunol 2007; 178: 2623-29.
12. Tilg HE, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J Exp Med 1993; 178: 1629-36.
13. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113-8.
14. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-68.
15. Tamai M, Kawakami A, Tanaka F, et al. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-γ through JAK/STAT pathway by translational regulation. J Lab Clin Med 2006; 147: 182-90.
16. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002; 169: 6610-6.
17. O'Shea JJ. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 2004; 63(Suppl 2): ii67-ii71.
18. Kinjyo I, Ohishi M, Shouda T, Kobayashi T, Yoshimura A. Positive and negative role for IL-6, STAT3, and SOCS3 in inflammatory arthritis. Adv Exp Biol Med 2007; 602: 113-24.
19. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005; 32: 1650-3.
20. Liu H, Huang Q, Shi B, Eksarko P, Temkin V, Pope RM. Regulation of Mcl-1 expression in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2006; 54: 3174-81.
21. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17: 406-12.
22. Schreiber S, Rosenstiel P, Hampe J, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002; 51: 379-85.
23. Mudter J, Weigmann B, Bartsch B, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005; 100: 64-72.
24. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 2008; 12: 171-83.
25. Musso A, Dentelli P, Carlino A, et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005; 11: 91-8.
26. Grote K, Luchtefeld M, Schieffer B. JANUS under stress- Role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 2005; 43: 357-63.
27. Bright JJ. Curcumin and autoimmune disease. Adv Exp Biol Med 2007; 595: 425-51.
28. Valentino L, Pierre J. JAK/STAT signaling: Regulators and implication in hematological malignancies. Biochem Pharmacol 2006; 71: 713-21.
29. Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Curr Rheum Rev 2005; 1: 131-42.
30. Malemud CJ. Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. Mini Rev Med Chem 2006; 6: 689-98.
31. Malemud CJ. Inhibitors of stress-activated/mitogen-activated protein kinase pathways. Curr Opin Pharmacol 2007; 7: 339-43.
32. Leonard WJ, O'Shea JJ. JAKS and STATs: Biological implications. Annu Rev Immunol 1998; 16: 293-322.
33. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000; 20: 3387-95.
34. Giordanetto P, Kroemer RT. Prediction of the structure of human Janus kinase (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002; 15: 727-37.
35. Haan S, Margue C, Engrand A, et al. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 2008; 180: 998-1007.
36. Ivashkiv LB. Cytokines and STATs: how can signals achieve specificity? Immunity 1995; 3: 1-4.
37. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-37.
38. Darnell JR Jr. STATs and gene regulation. Science 1997; 277: 1630-5.
39. Välineva T, Yang J, Palovuori R, Silvennoinen O. The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between CREB-binding protein and STAT6. J Biol Chem 2005; 280: 14989-96.
40. Kwon M-C, Koo B-K, Moon J-S, et al. Crif1 is a novel transcriptional coactivator of STAT3. EMJO J 2008; 27: 642-53.
41. Strobl B, Arulampalam V, Is'harc H, et al. A completely foreign receptor can mediate an interferon-γ-like response. EMBO J 2001; 20: 5431-42.
42. Maritano D, Sugrue ML, Tininini S, et al. The STAT3 isoforms α and β have unique and specific functions. Nat Immunol 2004; 5: 401-9.
43. Jaruga B, Hong F, Kim W-H, Gao B. IFN-γ/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1044-52.
44. Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol 2001; 166: 7276-81.
45. Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R. Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J Immunol 2003; 171: 3627-35.
46. Heim MH. The Jak-STAT pathway: signaling from the receptor to the nucleus. J Recept Signal Transduct Res 1999; 19: 75-120.
47. Kaplan MH. STAT4. A critical regulator of inflammation in vivo. Immunol Res 2005; 31: 231-42.
48. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-62.
49. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-70.
50. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-26.
51. Bovolenta C, Camorali L, Lorini AL, et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 1999; 94: 4202-9.
52. El Kasmi KC, Holst J, Coffre M, et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol 2006; 177: 7880-8.
53. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokineinducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14: 2816-26.
54. Iwamoto T, Senga T, Naito Y, et al. The JAK inhibitor, JAK/SOCS-1 selectively inhibits cytokine-induced, but not v-Srcinduced JAK-STAT activation. Oncogene 2000; 19: 4795-801.
55. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol 2001; 70: 348-56.
56. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 2005; 7: 100-10.
57. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999; 274: 35553-61.
58. Krebs DL, Hilton DJ. SOCS proteins: Negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-87.
59. Giordanetto F, Kroemer RT. A three-dimensional model of Suppressor of Cytokine Signaling-1 (SOCS-1). Protein Eng 2003; 16: 115-24.
60. De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M. SH2 domains from suppressor of cytokine-signaling-3 and protein phosphatase SHP-2 have similar binding specificities. Biochemistry 2002; 41: 9229-36.
61. Zhang J, Somani AK, Siminovitch KA. Roles of SHP-1 tyrosine phosphatase in the negative regulation of cell signaling. Semin Immunol 2000; 12: 361-378.
62. Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol 2000; 12: 349-59.
63. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 2006; 16: 196-202.
64. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004; 73: 355-82.
65. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19: 414-22.
66. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 2006; 67: 1-9.
67. Chinen T, Kobayashi T, Ogata H, et al. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFN-γ and IL-4 are involved. Gastroenterology 2006; 130: 373-88.
68. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001; 108: 1781-88.
69. Dong J, Wang Q-X, Zhou C-Y, Ma X-F, Zhang Y-C. Activation of the STAT1 signaling pathway in lupus nephritis in MRL/lpr mice. Lupus 2007; 16: 101-9.
70. Isomäki P, Alanärä T, Isohanni P, et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1538-46.
71. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-81.
72. Yoshida T, Ogata H, Kamio A, et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004; 199: 1701-7.
73. Müller-Ladner U, Judex M, Ballhorn W, et al. Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol 2000; 164: 3894-901.
74. Yokota A, Narazaki N, Shima Y, et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J Rheumatol 2001; 28: 1952-9.
75. Kasperkovitz PV, Verbeet NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 233-9.
76. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006; 65: 149-56.
77. Walker JG, Ahern MG, Coleman M, et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 992-9.
78. Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65: 1558-64.
79. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway. J Immunol 2001; 166: 3491-8.
80. El Mabrouk M, Sylvester J, Zafarullah M. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta 2007; 1773: 309-20.
81. Chesnokova V, Melmed S. Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 2002; 143: 1571-4.
82. Denko CW, Malemud CJ. The serum growth hormone to somatostatin ratio is skewed upward in rheumatoid arthritis patients. Front Biosci 2004; 9: 1660-4.
83. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fatderived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
84. Brentano F, Schorr O, Ospelt C, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 2829-39.
85. Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony enhancing factor by STAT-3-dependent interleukin-6 trans-signaling. Implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006; 54: 2084-95.
86. Nile CR, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008; 58: 2686-93.
87. Lubberts E, Koenders MI, van den Berg WB. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
88. Koenders MI, Lubberts E, van de Loo FAJ, et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J Immunol 2006; 176: 6262-9.
89. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 2006; 18: 349-56.
90. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6: 169-75.
91. Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of the JAK/STAT pathway in the signaling mechanism of IL-17. Biochem Biophys Res Commun 1999; 262: 14-9.
92. Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282: 9358-63.
93. Kimura A, Naka T, Kishimoto T. IL-6 dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007; 104: 12099-104.
94. h with a minimum effect on that of Treg in the steady state. Int Immunol 2007; 19: 695-702.
95. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19: 400-8.
96. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17 producing T cells. J Exp Med 2008; 205: 1543-50.
97. + regulatory T cell function. Science 2008; 322: 271-5.
98. Chikuma S, Murakami M, Tanaka K, Uede T. Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4. J Cell Biochem 2000; 78: 241-50.
99. Fallarino F, Bianchi R, Orabona C, et al. CTLA-4-Ig activates forkhead transcriptional factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200: 1051-62.
100. Orabona C, Belladonna ML, Vacca C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005; 174: 6582-6.
101. Johnston JA, O'Shea JJ. Matching SOCS with function. Nat Immunol 2003; 4: 507-9.
102. Hervey PS, Keam SJ. Abatacept. BioDrugs 2006; 20: 53-61.
103. Chen Z, Laurence A, Kanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006; 103: 8137-42.
104. Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 2006; 177: 1679-88.
105. Cheon H, Rho YH, Choi SJ, et al. Prostaglandin E2 augments IL-10 signaling and function. J Immunol 2006; 177: 1092-100.
106. Qin H, Wilson CA, Roberts KL, Baker BJ, Zhao X, Benveniste EN. IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine-signaling-3. J Immunol 2006; 177: 7761-71.
107. Timmer TCG, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology. Identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007; 56: 2492-502.
108. Lee H-S, Remmers EF, Le JM, Kastner DL, Bae S-C, Gregersen PK. Association of STAT4 with rheumatoid arthritis in the Korean population. Mol Med 2007; 13: 455-60.
109. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Eng J Med 2007; 357: 977-86.
110. Martínez A, Veradé J, Márquez A, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum 2008; 58: 2598-602.
111. Malemud CJ, Schulte ME. Is there a final common pathway for arthritis? Future Rheumatol 2008; 3: 253-68.
112. Cross A, Edwards SW, Bucknall RC, Moots RJ. Secretion of oncostatin M by neutrophils in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1430-6.
113. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford) 1999; 38: 714-20.
114. Collin-Osdoby P, Rothe L, Bekker S, Anderson F, Huang Y, Osdoby P. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on chick chorioallantoic membrane and activates isolated osteoclast resorption in vitro. J Bone Miner Res 2002; 17: 1859-71.
115. Krejci P, Prochazkova J, Bryja V, et al. Fibroblast growth factor inhibits interferon-γ-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal 2009; 21: 151-60.
116. Finnegan A, Grusby MJ, Kaplan CD, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002; 169: 3345-52.
117. + T cells. J Exp Med 2006; 203: 1459-70.
118. Katz JA, Itoh J, Fiocchi C. Pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 1999; 15: 291-7.
119. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-9.
120. Yu Y, Zeng H, Vijay-Kumar M, et al. STAT signaling underlies difference between flagellin-induced and tumor necrosis factor-α-induced epithelial gene expression. J Biol Chem 2004; 279: 35210-8.
121. Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45-9.
122. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and regulation. Biochem J 2003; 374: 1-20.
123. Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006; 55: 1263-69.
124. Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777-81.
125. Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways. Analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann NY Acad Sci 2006; 1072: 98-113.
126. Mitsuyama K, Matsumoto S, Masuda J, et al. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res 2007; 27: 3749-56.
127. Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007; 11: 613-24.
128. Debidda M, Wang L, Zang H, Poli V, Zheng Y. A role of STAT3 in the Rho GTPase-regulated cell migration and proliferation. J Biol Chem 2005; 280: 17275-85.
129. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 2: 243-9.
130. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 2008; 101: 89E-103E.
131. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90: 464-70.
132. Kaplan RC, Frishman WH. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 2001; 3: 326-32.
133. Engström G, Hedblad B, Tydén P, Lindgärde F. Inflammationsensitive plasma proteins are associated with increased incidence of heart failure: A population-based cohort study. Atherosclerosis 2009; 202: 617-22.
134. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 1998; 10: 248-53.
135. Frank GD, Mifune M, Inagami T, et al. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: Role of metalloproteinase and protein kinase C- delta. Mol Cell Biol 2003; 23: 1581-89.
136. Sano M, Fukuda K, Kodama H, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275: 29717-23.
137. El-Adawi H, Deng L, Tramontano A, et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 2003; 57: 129-38.
138. Kurdi M, Randon J, Cerutti C, Bricca G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 2005; 269: 95-101.
139. Hamanaka I, Saito Y, Yasukawa H, et al. Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo. Circ Res 2001; 88: 727-32.
140. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 106: 1442-6.
141. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003; 107: 798-802.
142. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 2007; 102: 279-97. Correction: Basic Res Cardiol 2007; 102: 393-411.
143. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 2008; 153(Suppl 1): S414-27.
144. Yasukawa H, Hoshijima M, Gu Y, et al. Suppressor of cytokine signaling-3 is a biochemical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 2001; 108: 1459-67.
145. Maya-Monteiro CM, Bozza PT. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle 2008; 7: 1713-7.
146. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10: 47-50.
147. Kriesel JD. The roles of inflammation, STAT transcription factors, and nerve growth factor in viral reactivation and herpes keratitis. DNA Cell Biol 2002; 21: 475-81.
148. Fan H, Walters CS, Dunston GM, Tackey R. IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 2002; 19: 126-37.
149. Killedar SJ, Eckenrode SE, McIndoe RA, et al. Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease in nod mouse using microarray analysis. Lab Invest 2006; 86: 1243-60.
150. Fasler-Kan E, Wunderlich K, Hildebrand P, Flammer J, Meyer P. Activated STAT 3 in choroidal neovascular membranes of patients with age-related macular degeneration. Ophthalmologica 2005; 219: 214-21.
151. Dudley AC, Thomas D, Best J, Jenkins A. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J 2005; 390: 427-36.
152. Fischer D, Hauk TG, Müller A, Thanos S. Crystallins of the (/(-superfamily mimic the effects of lens injury and promote axon regeneration. Mol Cell Neurosci 2008; 37: 471-9.
153. Huang Y, Cen L-P, Choy KW, et al. JAK/STAT pathway mediates retinal ganglion cell survival after acute ocular hypertension but not under normal conditions. Exp Eye Res 2007; 85: 684-95.
154. Jonsson R, Dowman SJ, Gordon T. Sjögren's syndrome. In: Koopman W Ed, Arthritis and Allied Conditions-A Textbook in Rheumatology, 15th Edition. Philadelphia, Lippincott Williams & Wilkins: 2004; 1681-1705.
155. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum 2002; 46: 1390-8.
156. Feigl B. Age-related maculopathy in light of ischaemia. Clin Exp Optom 2007; 90: 263-71.
157. Noecker RJ. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag 2006; 2: 193-206.
158. Heinrich PC, Behrmann I, Müller-Newen G, Schaper, Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem J 1998; 334: 297-314.
159. Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL6beta receptor components. Science 1994; 263: 92-5.
160. Heim MH, Kerr IM, Stark GR, Darnell JR Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995; 267: 1347-9.
161. Hemmann U, Gerhartz C, Hessel B, et al. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of Stat factor activation. J Biol Chem 1996; 271: 12999-3007.
162. Jostock T, Müllberg J, Özbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268: 160-7.
163. Nishimoto N, Kishimoto K. Humanized antihuman IL-6 antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-60.
164. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-40.
165. Metz S, Wiesinger M, Vogt M, et al. Characterization of the interleukin (IL)-6 inhibitor IL6-RFP. Fused receptor domains act as high affinity cytokine-binding proteins. J Biol Chem 2007; 282: 1238-48.
166. Chao KC, Chao KF, Chuang CC, Liu SH. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg 2006; 93: 332-8.
167. Yin F, Li P, Zheng M, et al. Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem 2003; 278: 21070-5.
168. Metz S, Naeth G, Heinrich PC, Müller-Newen G. Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors. J Biol Chem 2008; 283: 5985-95.
169. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
170. Chen Q, Carroll HP, Gadina M. The newest interleukins: Recent additions to the ever-growing cytokine family. Vitam Horm 2006; 74: 207-28.
171. Snyder M, Huang XY, Zhang JJ. Identification of novel direct Stat3 target proteins for control of growth and differentiation. J Biol Chem 2008; 283: 3791-8.
172. Choi JD, Bae SY, Hong JW, et al. Identification of the most active interleukin-32 isoform. Immunology 2009; 126: 535-42.
173. Bode JG, Schweigart J, Kehrmann J, et al. TNF-α induces tyrosine phosphorylation and recruitment of the Src homology proteintyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex. J Immunol 2003; 171: 257-66.
174. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT pathway. Oncogene 2000; 19: 2645-56.
175. Messerschmidtt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008; 466: 2168-75.
176. Yabu JM, Vincenti F. Novel immunosuppression: Small molecules and biologics. Semin Nephrol 2007; 27: 479-86.
177. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood 2008; 111: 2155-7.
178. http://www.secinfo.com/d11MXs.u2gp4.b.htm (February 4, 2009).
179. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51-7.
180. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10: R14.
181. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P. The JAK-3 inhibitor, CP-690550 is a potent antiinflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008; 582: 154-61.
182. Cao X, Shores EW, Hu-Li J, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995; 2: 223-38.
183. http://www.asx.com.au/asxpdf/20080731/pdf/31bg1crwqz4w8t.pdf.
184. Fridman J, Scherle P, Collins R, et al. Preclinical characterization of INCB02850, JAK1/JAK2 selective clinical candidate. Arthritis Rheum 2008; 58(Suppl): S296-S297 [Abstract].
185. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-20.
186. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008; 13: 321-30.
187. V617F mutation. Cancer Sci 2008; 99: 1265-73.
188. Dinan L, Whiting P, Girault J-P, et al. Cucurbitacins are insect steroid hormone antagonists acting at the ecdysteroid receptor. Biochem J 1997; 327: 643-50.
189. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-9.
190. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24: 3236-45.
191. Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using Type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008; 180: 2089-98.
192. Hussain SF, Kong L-Y, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67: 9630-6.
193. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26: 2435-44.
194. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004; 3: 1533-42.
195. Nefedova Y, Cheng P, Gilkes D, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175: 4338-46.
196. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173: 3844-54.
197. Levitski A. Tyrphostins-potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 1990; 40: 913-8.
198. Kirken RA, Erwin RA, Taub D, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated T cells. J Leukoc Biol 1999; 65: 891-99.
199. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inihibitor. Nature 1996; 379: 645-8.
200. Burke WM, Jin X, Lin H-J, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001; 20: 7925-34.
201. De Vos M, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogenactivated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823-28.
202. Shinjo K, Takeshita A, Ohnishi K, Ohno R. Granulocyte colonystimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk Lymphoma 1997; 25: 37-46.
203. Tian S-S, Lamb P, King AG, et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science 1998; 281: 257-9.
204. Doyle ML, Tian SS, Miller SG, et al. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by low molecular weight non peptidyl ligand. J Biol Chem 2003; 278: 9426-34.
205. Fabian MA, Biggs WH III, Treiber DK, et al. A small moleculekinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-36.
206. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
207. Pagano MA, Bain J, Kazimierczuk Z, et al. The selectivity of inhibitors of protein kinase CK2, an update. Biochem J 2008; 415: 353-65.
208. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood 2000; 96: 1655-69.
209. Han J-Y, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1( and antiangiogenic activity of farnesyltransferase inhibitor SCH663336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005; 97: 1272-86.
210. Dowlati A, Kluge A, Nethery D, Halmos B, Kern JA. SCH663336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/ human epidermal growth factor receptor 2. Anticancer Drugs 2008; 19: 9-16.
211. Malemud CJ. Growth hormone, VEGF and FGF: Involvement in rheumatoid arthritis. Clin Chim Acta 2007; 375: 10-9.
212. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NY Hosp Joint Dis 2007; 65(Suppl 1): S4-10.
213. Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotech 2008; 26: 957-9. Erratum: Nat Biotech 2008; 26: 1383.
214. Emery P, Keystone E, Tony H-P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to tumour necrosis factor biologicals: results for a 24-week multicentre randomized placebo controlled trial. Ann Rheum Dis 2008; 57: 1516-23.
215. http://clinicaltrials.gov/ct2/show/NCT00603512 (February 4, 2009).
216. http://clinicaltrial.gov/ct2/show/NCT00615199 (February 4, 2009).
217. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80.
218. Maini RN, Taylor PC, Szechinski J, et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor, antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
219. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study). A double-blind, placebo-controlled randomised trial. Lancet 2008; 371: 987-97.
220. Smolen JS, Beaulieu AD, Dikranian A, et al. Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008; 58 (Suppl): S784 [Abstract].
221. Hampton T. Arthritis clinical trials revealed. JAMA 2007; 297: 28-9.
222. http://clinicaltrial.gov/ct2/show/NCT00678210 (February 4, 2009).
223. Wilkinson B, Chow V, LaBadie R, Zwillich Sh, Cohen S. Coadministration of an oral JAK inhibitor CP690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58(Suppl): S297 [Abstract].
224. http://www.incyte.com (February 4, 2009).
225. Williams W, Scherle P, Shi P, et al. A randomized placebocontrolled study of INCB018424, a selective janus kinase 1&2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum 2008; 58 (Suppl): S431 [Abstract].
226. Takeshita T, Arita T, Higuchi M, et al. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity 1997; 6: 449-57.
227. Schneider H, Cal YC, Prasad KV, Shoelson SE, Rudd CE. T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras. Eur J Immunol 1995; 25: 1044-50.
228. Liu X, Wang L, Zhao K, et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008; 451: 846-50.
229. Liu Y-C. Ubiquitin ligases and the immune response. Annu Rev Immunol 2004; 22: 81-127.
230. Majumder S, Zhou LZ-H, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. p48/STAT-1α-containing complexes play a predominant role in induction of IFN-γ-inducible protein, 10 kDa (IP-10) by IFN- gamma; alone or in synergy with TNF-α. J Immunol 1998; 161: 4736-44.
231. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008; 283: 20635-44.
232. Lim J, Yusoff P, Wong ESM, et al. The cysteine-rich sprouty translocation domain targets mitogen-activated protein kinase inhibitory proteins to phosphatidylinositol 4, 5-bisphosphate in plasma membranes. Mol Cell Biol 2002; 22: 7953-66.
233. Bundschu K, Walter U, Schuh K. The VASP-Spred-Sprouty domain puzzle. J Biol Chem 2006; 281: 36477-81.
234. Bundschu K, Walter U, Schuh K. Getting a first clue about SPRED functions. Bioessays 2007; 29: 897-907.
235. Yammani RR, Long D, Loeser RF. Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocyes. Arthritis Rheum 2009; 60: 792-800.